BridgeBio Pharma, Inc.
BBIO evidence brief
What we can confirm
- BioSniper Score:
- 2.7 / 10
- Market Cap:
- $14.62B
- Next Catalyst:
- Patent_Expiry · Apr 9, 2029
What it means
What to watch
Prepared research question
What matters most for BBIO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BBIO
BridgeBio Pharma, Inc. (BBIO) is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases [sec_mda · as of 2026-08-10].
Key risk: Negative shareholders' equity
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 5 clinical trials · 3 catalysts for BridgeBio Pharma, Inc..
BridgeBio Pharma, Inc. (BBIO) is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases [sec_mda · as of 2026-08-10].
- BridgeBio is a commercial-stage, multi-product biopharmaceutical company focused on genetic diseases [sec_mda · as of 2026-08-10].
- As of 2026-06-30, the company reported cash & equivalents of $677.9M, total revenue of $243.7M, and shareholders' equity of -$2,515.2M [sec].
- BridgeBio plans four global launches by 2027, with Attruby nearing blockbuster status [news · published 2026-09-26].
- The company submitted an NDA to the FDA for low-dose infigratinib for achondroplasia and has a PDUFA target action date of May 8, 2027 for encaleret [sec_mda · as of 2026-08-10].
- Interim Phase 3 FORTIFY trial data for BBP-418 in limb-girdle muscular dystrophy type 2I/R9 met efficacy endpoints [news · published 2026-03-08].
What works
- BridgeBio has a robust pipeline with multiple late-stage programs, including Attruby (approved for ATTR-CM) and BBP-418 (positive Phase 3 interim data) [news · published 2026-03-08] [pipeline].
- The company expects to expand from one commercial product to four globally launched therapies by 2027, indicating strong commercial momentum [news · published 2026-09-26].
- BridgeBio maintains a substantial cash position of $677.9M as of 2026-06-30, providing financial runway for development and commercialization [sec].
What to weigh
- BridgeBio has a negative shareholders' equity of -$2,515.2M as of 2026-06-30, indicating significant accumulated losses [sec].
- The company faces substantial expenses for later-stage clinical trials and may not generate significant revenues from product sales even if approved [sec_mda · as of 2026-08-10].
- BridgeBio has contingent payment obligations under various license and collaboration agreements that could increase financial liabilities [sec_mda · as of 2026-08-10].
From the filings
Quoted directly from source documents.
BridgeBio is a commercial-stage, multi-product biopharmaceutical company focused on genetic diseases.
“BridgeBio Pharma, Inc. ("BridgeBio," the "Company," or "we"), is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases.”
SEC MD&A · August 10, 2026
BridgeBio plans four global launches by 2027.
“BridgeBio Pharma (NASDAQ:BBIO) expects 2027 to be a transformative year as it expands from one commercial product to four globally launched therapies”
News · September 26, 2026
Interim Phase 3 FORTIFY trial data for BBP-418 met efficacy endpoints.
“BridgeBio Pharma, Inc. recently announced that interim Phase 3 FORTIFY trial data for BBP-418 in limb-girdle muscular dystrophy type 2I/R9 met efficacy endpoints”
News · March 8, 2026
BridgeBio submitted an NDA for low-dose infigratinib for achondroplasia.
“We submitted our NDA to the FDA for low-dose infigratinib for achondroplasia.”
SEC MD&A · August 10, 2026
Catalyst timeline
- 2029-04-09 · Patent_Expiry · FOSDENOPTERIN HYDROBROMIDE — Patent expiry for NDA214018; may affect exclusivity for this product.
- 2034-12-11 · Patent_Expiry · INFIGRATINIB PHOSPHATE — Patent expiry for NDA214622; may affect exclusivity for this product.
- 2039-08-16 · Patent_Expiry · ACORAMIDIS HYDROCHLORIDE — Patent expiry for NDA216540; may affect exclusivity for Attruby.
Risks & what to watch (3)›
Key risks
- Negative shareholders' equity — Shareholders' equity of -$2,515.2M as of 2026-06-30 indicates substantial accumulated losses [sec].
- Uncertain revenue generation — Company may not generate significant revenues from product sales even if approved [sec_mda · as of 2026-08-10].
- Contingent payment obligations — Milestone and royalty obligations under license agreements could increase financial liabilities [sec_mda · as of 2026-08-10].
What to watch
- PDUFA target action date of May 8, 2027 for encaleret [sec_mda · as of 2026-08-10].
- Expansion from one to four global launches by 2027, including Attruby and other pipeline candidates [news · published 2026-09-26].
- Commercial performance of Attruby and its potential to reach blockbuster status [news · published 2026-09-26].
- Regulatory decisions on NDAs for low-dose infigratinib (achondroplasia) and BBP-418 (LGMD2I/R9) [sec_mda · as of 2026-08-10] [news · published 2026-03-08].
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 6, 2026 · How we verify sources →
Run BridgeBio Pharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BridgeBio Pharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
N/A
No tracked pipeline phase
No tracked pipeline candidates
3 upcoming, next in ~908d
0 buys · 55 sells (180d)
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
457
Total value held
$13.92B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 14,207,757 | $1.06B |
| kohlberg kravis roberts & co. l.p. | 13,260,971 | $984.8M |
| janus henderson group plc | 13,179,013 | $978.6M |
| viking global investors lp | 11,842,434 | $879.4M |
| farallon capital management llc | 9,365,463 | $695.5M |
| vanguard portfolio management llc | 8,080,573 | $600.1M |
| vanguard capital management llc | 7,759,495 | $576.2M |
| aisling capital management lp | 5,089,611 | $378.0M |
| geode capital management, llc | 4,918,030 | $371.9M |
| state street corp | 4,934,320 | $366.4M |
Showing top 10 of 457 institutional holders of BridgeBio Pharma, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 13.7%
- Days to cover
- 9.8
- Shares short
- 24,026,982
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BBIO short interestGovernance
Frequently asked questions
What is the AI investment thesis for BridgeBio Pharma, Inc.?
BridgeBio Pharma, Inc. (BBIO) is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases [sec_mda · as of 2026-08-10].
What is BridgeBio Pharma, Inc.'s next catalyst?
BridgeBio Pharma, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA214018" — expected April 9, 2029.
Who is the CEO of BridgeBio Pharma, Inc.?
Dr. Neil Kumar Ph.D. is the chief executive officer of BridgeBio Pharma, Inc. (BBIO).
Where is BridgeBio Pharma, Inc. headquartered?
BridgeBio Pharma, Inc. (BBIO) is headquartered in Palo Alto, CA, United States.
What therapeutic areas does BridgeBio Pharma, Inc. focus on?
BridgeBio Pharma, Inc. develops therapies across Oncology, Rare Disease, Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.